主页 / 细胞生物学 / Signal Transduction / Transcription Factors / Nrf2 / Nrf2 Inhibitors / ML 385

ML 385

Cat. No. 6243 2 篇引用文献 提交评论 说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）
Pricing Availability   Qty
说明： Nrf2 inhibitor; phenotypically lethal
化学名： N-[4-[2,3-Dihydro-1-(2-methylbenzoyl)-1H-indol-5-yl]-5-methyl-2-thiazolyl]-1,3-benzodioxole-5-acetamide
纯度： ≥98% (HPLC)
说明书
引用文献 (2)
评论
文献 (2)
生物活性 技术数据 溶解性 计算器 说明书 参考文献

生物活性 for ML 385

ML 385 is an Nrf2 inhibitor. Blocks Nrf2 downstream target gene expression. Enhances cytotoxic effects of doxorubicin (Cat. No. 2252) or Taxol (Cat. No. 1097) in non-small cell lung cancer (NSCLC). Demonstrates selectivity for NSCLC cells with KEAP1 mutations.

化合物库 for ML 385

ML 385 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for ML 385

分子量 511.59
公式 C29H25N3O4S
储存 Store at -20°C
纯度 ≥98% (HPLC)
CAS Number 846557-71-9
PubChem ID 1383822
InChI Key LINHYWKZVCNAMQ-UHFFFAOYSA-N
Smiles CC1=C(C2=CC=C3N(C(C4=C(C=CC=C4)C)=O)CCC3=C2)N=C(S1)NC(CC5=CC=C6OCOC6=C5)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for ML 385

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 25.58 50

制备储备液 for ML 385

以下数据基于产品分子量 511.59。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
0.5 mM 3.91 mL 19.55 mL 39.09 mL
2.5 mM 0.78 mL 3.91 mL 7.82 mL
5 mM 0.39 mL 1.95 mL 3.91 mL
25 mM 0.08 mL 0.39 mL 0.78 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

参考文献 for ML 385

参考文献是支持产品生物活性的出版物。

Singh et al (2016) Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem.Biol. 11 3214 PMID: 27552339

If you know of a relevant reference for ML 385, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Nrf2 Inhibitors

关键词: ML 385, ML 385 supplier, ML385, Nrf2, snhibitors, cytotoxic, non-small, cell, lung, cancer, NSCLC, phenotypically, lethal, 6243, Tocris Bioscience

2 篇 ML 385 的引用文献

引用文献是使用了 Tocris 产品的出版物。 ML 385 的部分引用包括：

Jeong Hwan et al (2020) Capsosiphon fulvescens Glycoproteins Enhance Probiotics-Induced Cognitive Improvement in Aged Rats. Nutrients 12 PMID: 32245093

Steven C et al (2023) Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging. Acta Neuropathol Commun 11 6 PMID: 36631900

您是否知道使用了 Tocris ML 385 的优秀论文？ 请告知我们.

ML 385 的评论

目前没有该产品的评论。 Be the first to review ML 385 and earn rewards!

Have you used ML 385?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。

Cancer Metabolism Research Product Guide

Cancer Metabolism Research Product Guide

This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:

Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.